Authors
Huiyuan Guan, Changzhou Cai, Jiewei Wang, Zhaoxue Liu, Jin Peng, Xupeng Bai, Lingzhi Wu, Kun Jiang, Xinghua Zhen, Chaohui Yu, Pumin Zhang, Zhe Shen
Published in
The Journal of biological chemistry. Pages 113420. Aug 13, 2026. Epub Aug 13, 2026.
Abstract
Inflammatory bowel disease (IBD) is characterized by unresolved mucosal inflammation driven mainly by TNFα and/or IFNγ. While anti-TNFα biologics are a clinical mainstay, therapeutic resistance remains a significant hurdle. The molecular mechanisms that sustain inflammation in anti-TNFα non-responders are not fully understood. In human colon biopsies, we identified significant upregulation of the deubiquitinase OTUD5 in non-responders compared to responders, suggesting its involvement in therapy resistance. Using an intestinal epithelial cell (IEC)-specific Otud5 knockout mouse model, we show that Otud5 deficiency significantly alleviated the IFNγ-dependent colitis induced by dextran sulfate sodium (DSS), as evidenced by reduced weight loss and diminished infiltration of Ly6C+ inflammatory monocytes. Mechanistically, IFNγ induces OTUD5 expression through a non-transcriptional mechanism; in turn, OTUD5 stabilizes STAT1 and STAT2 by preventing their ubiquitination and subsequent degradation. This sustains IFNγ-ISGF3 signaling, which directly drives the expression of CCL8, a critical chemokine for monocyte recruitment. Targeting this pathway with a newly identified small-molecule inhibitor, CT1170, which exhibits potent activity against OTUD5, blocked the IFNγ-ISGF3-CCL8 axis, halted colitis progression, and suppressed colitis-elicited tumorigenesis. These findings were validated in human IBD organoids, where CT1170 effectively disrupted IFNγ-driven inflammatory signaling.
PMID:
42595111
Bibliographic data and abstract were imported from PubMed on 14 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0